Israelis lack sleep and experience high anxiety amid the wars with Hamas and Iran as the two Middle East nations exchange ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

Nucor shares are rising Wednesday after the steelmaker outlined better second-quarter profit projections than analysts had ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Global shares were mostly higher Wednesday and oil prices slipped as investors awaited a decision on interest rates by the ...

NEW YORK — U.S. stocks slumped Tuesday under the weight of another jump for the price of oil. It was a return to form for ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...